Review

Improving the use of research evidence in guideline development: 11. Incorporating considerations of cost-effectiveness, affordability and resource implications

Tessa Tan-Torres Edejer*

Address: Health Systems Financing, World Health Organization, CH-1211 Geneva 27, Switzerland

Email: Tessa Tan-Torres Edejer* - tantorrest@who.int

* Corresponding author

Abstract

Background: The World Health Organization (WHO), like many other organisations around the world, has recognised the need to use more rigorous processes to ensure that health care recommendations are informed by the best available research evidence. This is the 11th of a series of 16 reviews that have been prepared as background for advice from the WHO Advisory Committee on Health Research to WHO on how to achieve this.

Objectives: We reviewed the literature on incorporating considerations of cost-effectiveness, affordability and resource implications in guidelines and recommendations.

Methods: We searched PubMed and three databases of methodological studies for existing systematic reviews and relevant methodological research. We did not conduct systematic reviews ourselves. Our conclusions are based on the available evidence, consideration of what WHO and other organisations are doing and logical arguments.

Key questions and answers: When is it important to incorporate cost-effectiveness, resource implications and affordability considerations in WHO guidelines (which topics)?

• For cost-effectiveness:
  The need for cost/effectiveness information should be dictated by the specific question, of which several may be addressed in a single guideline. It is proposed that the indications for undertaking a cost-effectiveness analysis (CEA) could be a starting point for determining which recommendation(s) in the guideline would benefit from such analysis.

• For resource implications/affordability:
  The resource implications of each individual recommendation need to be considered when implementation issues are being discussed.

How can cost-effectiveness, resource implications and affordability be explicitly taken into account in WHO guidelines?

• For cost-effectiveness:
  ◦ If data are available, the ideal time to consider cost-effectiveness is during the evidence gathering and synthesizing stage. However, because of the inconsistent availability of CEAs and the procedural difficulty associated with adjusting results from different CEAs to make them comparable, it is also possible for cost-effectiveness to be considered during the stage of developing recommendations.
  ◦ Depending on the quantity and quality and relevance of the data available, such data can be considered in a qualitative way or in a quantitative way, ranging from a listing of the costs to a modelling exercise. At the very least, a qualitative approach like a commentary outlining the economic issues that need to be considered is necessary. If a quantitative approach is to be used, the full model should be transparent and comprehensive.
• For resource implications/affordability:
  ◦ Resource implications, including health system changes, for each recommendation in a WHO guideline should be explored. At the minimum, a qualitative description that can serve as a gross indicator of the amount of resources needed, relative to current practice, should be provided.

How does one provide guidance in contextualizing guideline recommendations at the country level based on considerations of cost-effectiveness, resource implications and affordability?

• All models should be made available and ideally are designed to allow for analysts to make changes in key parameters and reapply results in their own country.
• In the global guidelines, scenarios and extensive sensitivity/uncertainty analysis can be applied.

Resource implications for WHO
• From the above, it is clear that guidelines development groups will need a health economist. There is need to ensure that this is included in the budget for guidelines and that there is in-house support for this as well.

Background
The World Health Organization (WHO), like many other organisations around the world, has recognised the need to use more rigorous processes to ensure that health care recommendations are informed by the best available research evidence. This is the 11th of a series of 16 reviews that have been prepared as background for advice from the WHO Advisory Committee on Health Research to WHO on how to achieve this. In this paper we address the following questions:

• When is it important to incorporate cost-effectiveness, resource implications and affordability considerations in WHO guidelines (which topics)?

• How can cost-effectiveness, resource implications and affordability be explicitly taken into account in WHO guidelines?

• How does one provide guidance in contextualizing guideline recommendations at the country level based on considerations of cost-effectiveness, resource implications and affordability?

• What are the resource implications of the answers to these questions for WHO?

What is WHO doing now?
In 2003, the Guidelines for WHO Guidelines [1] recommended that both cost-effectiveness and resource implications of guideline recommendations be considered when developing WHO guidelines. With the primary audience being Ministry of Health officials with a mandate to improve population health rather than the health of individuals, such concerns were considered to be appropriate. The guidelines (see Additional file 1 for relevant portions) states very briefly that cost-effectiveness is to be considered during the stage of formulation of the recommendations and that the recommendations could be expressed in terms of scenarios (for countries with limited versus some resources). It also recommends that 1–2 experts in cost-effectiveness analysis (CEA) be involved in the technical guidelines development group. Finally, in the third stage or the localization phase in-country, it suggests that WHO provide technical assistance for countries to use their own or regional cost-effectiveness information and that WHO also provide information on financial costs of implementing the recommendations.

There has been some mention of cost-effectiveness in a few guidelines that were issued since 2003 and that claim to have used the Guidelines for WHO Guidelines. The 2003 WHO/ISH guidelines [2] had general sections on cost-effectiveness and resource implications of the recommendations. More recently, the WHO "guidelines" on hand hygiene in health care [3] also included information on economic burden of poor hygiene, cost-effectiveness and resource implications of recommendations. Another example, the malaria treatment guidelines [4] specifically state that cost-effectiveness studies were not included for consideration because there were very few completed studies relating to the interventions being considered, and that the prices of the anti-malarial drugs were fluid, "rendering such studies unreliable."

What other organizations are doing?
It is clear that cost-effectiveness and/or cost implications of recommendations are recognized in guideline development. The US Preventive Services Task Force [5] lists several reasons why CEA is useful in guideline development:

1. Quantifying the differences between two or more effective services for the same condition
2. Illustrating the impact of delivering a given intervention at different intervals, different ages, or to different risk groups

3. Evaluating the potential role of new technologies

4. Identifying key conditions that must be met to achieve the intended benefit of an intervention

5. Incorporating preferences for intervention outcomes

6. Developing a ranking of services in order of their costs and expected benefits

The AGREE guidelines appraisal instrument [6], on which the WHO checklist was loosely based, includes the cost impact of guideline recommendations under their applicability criteria.

To actually gauge what other organizations are doing with respect to cost-effectiveness/costs in guideline development, one can review the guidelines that have been issued by these organizations and/or review their documented methods for guideline development. It is hoped that there is consistency between the two. In 1999, 279 guidelines that were published in peer-reviewed literature were reviewed [7]. Only 41.6% made any mention of projected effects on health care costs, and only 14.3% quantified these estimates in any way. A 2002 study on the incorporation of published cost-effectiveness analysis in published clinical guidelines showed that, using guidelines as the unit of analysis, 9 of 35 (26%) incorporated at least 1 economic analysis of above-average quality in the text and 11 of 35 (31%) incorporated at least 1 in the references [8]. Finally, a search of the database of the National Guideline Clearinghouse [9] showed that of 1616 guidelines published between 2000–2005, only 369 or 23% had a formal cost analysis.

For a review of methods, a 2003 survey [10] of 18 clinical practice guideline development agencies showed that six included costs/cost containment/cost-effectiveness in their objectives but only three routinely included health economists in their guideline development groups (NHRMC in Australia, SBU in Sweden, and North of England). The AGREE prototype electronic library shows some illustrative excerpts specifically mentioning costs from the methodologies of five national agencies. More detailed information on the use of costs/cost-effectiveness information by guidelines agencies is available (see Additional file 2).

To what extent these organizations routinely and explicitly use costs/CEA in their guidelines is not clear. More information is needed on the actual experience of these organizations in incorporating costs/cost-effectiveness information during their guideline development process (e.g. lessons learned) [11] and an assessment of whether economic evaluations have provided added value to their guidelines [12].

Methods
The methods used to prepare this review are described in the introduction to this series [13]. Briefly, the key questions addressed in this paper were vetted amongst the authors of the series of articles and the ACHR Subcommittee on the Use of Research Evidence (SURE). We did not conduct full systematic reviews. We searched PubMed and three databases of methodological studies (the Cochrane Methodology Register, the US National Guideline Clearinghouse, and the Guidelines International Network for existing systematic reviews and relevant methodological research that address these questions. The answers to the questions are our conclusions based on the available evidence, consideration of what WHO and other organisations are doing, and logical arguments.

For this review PubMed was searched using the following text word searches: costs and generalizability, practice guidelines and cost-effectiveness analysis and combinations thereof. Using the same search words, the Internet search machine, Google, was also used to search for unpublished documents. Websites of known repositories of guidelines, of organizations of guideline agencies, and of pioneer/well-known guideline development agencies were visited. References in key documents that had titles which could be probably relevant were also pursued. A few times, when it was evident that an author had this as his/her special area of interest, a search using his/her name in connection with guidelines was also done. Papers were included if they described guidelines that included cost-effectiveness information, or described methods of guideline agencies to incorporate costs/resource implications/CEA information.

The information collected during the review was then synthesized where relevant for each question and was used as the basis to draw the implications for WHO guidelines.

Findings
When is it important to incorporate considerations of cost-effectiveness and resource implications of recommendations in WHO guidelines (which topics)?
The need for cost-effectiveness information should be dictated by the specific question of which several may be addressed in one guideline alone. It is proposed that the indications for undertaking a cost-effectiveness analysis could be a starting point for determining which recommendation(s) in the guideline would benefit from such analysis [14]. From the review, NHRMC states explicitly
that "the challenge is to focus on the decision points that are of key importance in an economic sense and pinpoint the nature of economic information needed to address these questions. The key decisions concern health care that contributes significantly to the total cost of an option, options with very different costs or care that contributes significantly to health outcomes. On the other hand, decisions are unimportant if they concern health care that is uncontroversial, options that are not economically viable or options for which there are no large resource implications." [15]

The UK National Institute for Health and Clinical Excellence (NICE) extends this concept by adopting a value of analysis approach where aside from "the overall 'importance' of the recommendation (which is a function of the number of patients affected and the potential impact on costs and health outcomes per patient)"; they also suggest evaluating "the current extent of uncertainty over cost-effectiveness and the likelihood that analysis will reduce this uncertainty" [16].

**Implications for WHO guidelines**

At the scoping stage, the assistance of an experienced health economist who is familiar with the area of interest would be needed and a selective identification of the issues needing CEA could be done. If CEA is not initially identified during the scoping stage as a clear need, this issue needs to be revisited again at the evidence, recommendations and peer review stage.

On the other hand, the resource implications of each individual recommendation needs to be considered when implementation issues are being discussed. This may be done at the global guideline level, through the use of scenarios, and at the local adaptation or country level.

**How can cost-effectiveness and affordability be explicitly taken into account in WHO guidelines?**

There are different points in the guideline development process that cost-effectiveness and resource implications of guidelines recommendations can be considered. The first phase is the evidence phase and to the extent possible, this is where cost-effectiveness information should be considered.

As in questions on effectiveness, the question can be raised as to why conduct a review of CEs rather than identify a single study that addresses the question? "CEAs vary widely in their methods and assumptions. Because of this variation, systematically reviewing CEs provides several benefits. First, because CEs draw on a variety of cost and effectiveness data sources to develop input parameters, a systematic review can identify which analyses use the best available evidence for key inputs and are therefore the most evidence based. Second, because the credibility of CEs rests on their quality, a critical review of CEs and a rating of the quality of each allow for identifying the most methodologically rigorous studies. Third, a comprehensive review can identify the studies that best address the question being asked. Fourth, comparatively assessing CEs can help to identify variables and methods that significantly influence the estimated benefits and cost effectiveness of an intervention. For instance, some CEs might assume no harms from a given intervention, while others might assume that the intervention has significant harms. Comparing these studies side by side may provide insight into how the assumption or lack of assumption of harm affects the estimated benefit of the intervention. While some assumptions are varied within a single study using sensitivity analysis, most CEs provide a limited number of sensitivity analyses. Thus, systematically reviewing CEs may help identify, through a side-by-side comparison that amounts to a "virtual sensitivity analysis," the impact of different assumptions on the benefits of a given intervention. Finally, the more high-quality, independently conducted CEs there are for a given intervention, the more convincing the evidence." [17]

In doing a systematic review of economic evaluations, the first step is to search for the literature. There are available resources on the internet which list databases and compilations of economic evaluations [18]. In addition, there has been a systematic evaluation in terms of sensitivity and specificity of different search strategies for economic evaluations [19].

In extracting data, considerable progress has been reported with development of a systematic process of adjustments of results from different studies to make them comparable. The Task Force on Community Preventive Services admits that "no process of adjustment or other means of reviewing existing economic evaluations is flawless." But it makes the point that to adjust data to make it comparable is better than to "(1) ignore economic information entirely; (2) attempt to use non-comparable data; or (3) adjust in ways that are not systematic or explicit" [20].

Some work has also been done in terms of very simple visual methods to present summaries of cost-effectiveness analysis [21]. Despite all of these advances methodologically, the current situation shows however, that there is limited availability and variable quality of relevant CEs [22].

**Implications for WHO guidelines**

If data is available, the ideal time to consider CEA is during the evidence gathering and synthesizing stage. However, because of the inconsistent availability of CEs and
the procedural difficulty associated with adjusting results from different CEs to make them comparable [20] it is also possible for CEA to be considered during the stage of developing recommendations. This is also consistent with the GRADE approach [23]. At this stage, the information of the resource implications and outcomes of the recommended interventions can be considered simultaneously. Depending on the quantity and quality and relevance of the data available, such data can be considered in a qualitative way or in a quantitative way, ranging from a listing of the costs to a modelling exercise [24,25]. At the very least, a qualitative approach like a commentary outlining the economic issues that need to be considered is necessary [26]. If a quantitative approach is to be used, the full model should be transparent, be made available and extensive uncertainty/sensitivity analysis built-in so as to allow analysts to selectively reapply results in their own country, as in the WHO-CHOICE contextualization tool [27].

How does one provide guidance in contextualizing guideline recommendations at the country level based on considerations of cost-effectiveness and affordability?

For cost-effectiveness, there are concerns about the generalizability of results from a single CEA or even a systematic review of a CEA. A review of sources of variability frequently mentions volume and costs of resources consumed as a source of variability [28]. Not as much work has been done on variability of outcomes. Very recently, a checklist was developed for assessing variability or generalizability to be able to translate information from one developed country to another [29]. There is a need to pilot test this, a revision or another instrument in developing countries. For costs, more specifically prices, general principles for adaptation are available [30].

Affordability or resource implications can be considered in the global guidelines if it gives guidance by provision of basic information that will allow guideline users to work out the cost implications for their own service [25,15]. A scenario approach can be used. Also, in this context, WHO-CHOICE data and methods are useful for contextualization [31]. Note that this exercise will also need to include the health system implications of the recommendations, from training, changes in supervision, monitoring and evaluation, advocacy, etc. as seen in some recent examples [32,33].

Implications for WHO

Resource implications, including health system changes, for each recommendation in WHO guidelines should be explored. At the minimum, a qualitative description that can serve as a gross indicator of the amount of resources needed, relative to current practice, should be provided.

Overall assessment of need for health economics expertise

In summary, the role of the health economist in a guideline development group is to:

- help to identify the clinical issues or questions for economic analysis
- review economic literature
- carry out or commission cost-effectiveness analyses
- estimate the cost and resource implications of the recommendations.

"The relative weight given to each role will vary from guideline to guideline. There may be large differences between guidelines in respect of the literature available to review: the size of the relevant economics literature, its relevance, its quality, its timeliness, its generalisability. In some areas there may be good-quality data that can be used in economic models, whereas other areas may have a dearth of such data." [16] Additionally, all throughout the process, the health economist can educate the other guideline development group about CEA and vice-versa, through interaction with the guideline development group members, s/he will be better able to work with an improved understanding of the health issues being considered.

Implications for WHO

From the above, it is clear that guidelines development groups will need access to a health economist. There is need to ensure that this is budgeted for in the resources and that there is in-house support for this as well.

Further work

There is a need to: 1) get more information on the actual experience of guideline agencies in incorporating CEA in guidelines; 2) assess the added value of economic evaluations in guidelines by comparing recommendations with and without CEA; 3) further expand the section on CEA and resource implications in guidelines, including specification of the minimum information that should be provided, in collaboration with health economists and experienced guideline developers.

Competing interests

The author helped to develop the current Guidelines for WHO Guidelines.

Authors’ contributions

TTE prepared the first draft of the review and was responsible for the subsequent revisions.
Additional material

Additional file 1
Cost-effectiveness and affordability in the Guidelines for WHO Guidelines. Excerpts from the document "Guidelines for WHO Guidelines" which refer to the concepts of cost-effectiveness and affordability.
Click here for file
[http://www.biomedcentral.com/content-supplementary/1478-4505-4-23-S1.doc]

Additional file 2
Considerations of cost-effectiveness information by other agencies. Excerpts from documents from other agencies that issue guidelines which refer to the concepts of cost-effectiveness
Click here for file
[http://www.biomedcentral.com/content-supplementary/1478-4505-4-23-S2.doc]

Acknowledgements
I gratefully acknowledge the members of the ACHR SURE, and all of those who have provided feedback on earlier versions of this paper.

References
1. Guidelines for WHO guidelines: World Health Organization. Global Programme on Evidence for Health Policy [http://whqlibdoc.who.int/hq/2003/EIP_GPE_EOC_2003_1.pdf].
2. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) guidelines statement on management of hypertension 2003 [http://www.who.int/cardiovascular_diseases/guidelines/hypertension_guidelines.pdf]. Lipincott, Williams and Wilkins
3. WHO guidelines on hand hygiene in health care (advanced draft): a summary: clean hands are safer hands 2005 [http://whqlibdoc.who.int/hq/2005/WHO_EIP_SPO_QPS_05.2.pdf]. World Health Organization. Dept. of Health System Policies and Operations
4. World Health Organization: Guidelines for the Treatment of Malaria Geneva, World Health Organization: 2006.
5. Saha S, Hoerger TJ, Pignone MP, Teutsch SM, Helfand M, Mandelblatt JS, Cost Work Group, Third US Preventive Services Task Force: The art and science of incorporating cost effectiveness into evidence-based recommendations for clinical preventive services. Am J Prev Med 2001, 20(3 Suppl):36-43.
6. The AGREE Collaboration: Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. 2001 [http://www.agreecollaboration.org/pdf/agreeinstrumentfinal.pdf].
7. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J: Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 281(20):1900-5. 1999 May 26
8. Wallace JF, Weingarten SR, Chiou CF, Henning JM, Hohlbauch AA, Richards MS, Herzog NS, Lewensohn LS, Ofman JJ: The limited incorporation of economic analyses in clinical practice guidelines. J Gen Intern Med 2002, 17(3):210-20.
9. National Guidelines Clearinghouse [http://www.guideline.gov].
10. Burgers JS, Grol R, Klazinga NS, Makela M, Zaai J. AGREE Collaboration: Towards evidence-based clinical practice: an international survey of 18 clinical guideline programs. Int J Qual Health Care 2003, 15(1):31-45.
11. Louis W, Niessen, Els Grijssel, Marc Koopmanschap and Frans Rutten. Economic analysis for clinical practice – the case of 31 national consensus guidelines in the Netherlands. Journal of Evaluation in Clinical Practice (forthcoming).
12. Granata AV, Hillman AL: Competing practice guidelines: using cost-effectiveness analysis to make optimal decisions. Ann Intern Med 128(1):56-63. 1998 Jan 1
13. Oxman AD, Fretheim A, Schunemann HJ: Improving the use of research evidence in guideline development: introduction. Health Res Policy Syst 2006.
14. Drummond Michael F, O'Brien Bernie, Stoddart Greg L, Torrance George W: Methods for the Economic Evaluation of Health Care Programs Second edition. Oxford University Press; 1997.
15. NHRMC: How to compare the costs and benefits: evaluation of the economic evidence Handbook series on preparing clinical practice guidelines; Endorsed July 2001. [http://www7.health.gov.au/nhrmc/publications/synopsis (cp73syn.htm)].
16. National Institute of Clinical Excellence: The Guidelines Manual. Incorporating health economics in guidelines and assessing resource impact Chapter 8: [http://www.nice.org.uk/page.asp?o=308777]. 25 April 2006.
17. Truman BI, Smith-Akin CK, Hinman AR, Gebbie KM, Brownson R, Novick LF, Lawrence RS, Pappaoanou M, Fielding J, Evans CA Jr, Guerra FA, Vogel-Taylor M, Mahan CS, Fulllove M, Zaza S: Developing the Guide to Community Preventive Services – overview and rationale. The Task Force on Community Preventive Services. Am J Prev Med 2000, 18(1 Suppl):18-26.
18. NHS Economic Evaluation Database [http://www.york.ac.uk/inst/cr/econ/].
19. Saps F, Archard L, McDaid D: Searching literature databases for health care economic evaluations: how systematic can we afford to be? Med Care 2002, 40(5):387-94.
20. Carande-Kulis VG, Maciosek MV, Briss PA, Teutsch SM, Zaza S, Trueman BI, Messonnier ML, Pappaoanou M, Harris JR, Fielding J: Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services. Am J Prev Med 2000, 18(1 Suppl):75-91.
21. Nixon J, Khan KS, Kleijnen J: Summarising economic evaluations in systematic reviews: a new approach. BMJ 322(7290):1596-8. 2001 Jun 30
22. Jefferson T, Demicheli V, Vale L: Quality of systematic reviews of economic evaluations in health care. JAMA 287(21):2809-12. 2002 Jun 5
23. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer TT, Varonen H, Vist GE, Williams JV Jr, Zaza S, GRADE Working Group: Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. 2004 Jun 19
24. Eccles M, Mason J: How to develop cost-conscious guidelines. Health Technol Assess 2001, 5(16):1-69.
25. Philips Z, Ginelly L, Sculpher M, et al.: Review of good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment 2004, 8(36).
26. SIGN 50: A guideline developers’ handbook [http://www.sign.ac.uk/guidelines/fulltext/50/section6.html].
27. CHOosing Interventions that are Cost Effective (WHO-CHOICE) [http://www.who.int/choice].
28. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, Davies LM, Eastwood A: Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 2004, 8(49):iii-ix, 1-92.
29. Boulenger S, Nixon J, Drummond M, Ulmann P, Rice S, de Pourvouville G: Can economic evaluations be made more transferable? Eur J Health Econ in press. 2005 Oct 26
30. Hutton G, Baltussen R: Cost valuation in resource-poor settings. Health Policy Plan 2003, 20(4):352-3.
31. Hutubessy R, Chisholm D, Edejer TT: Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1(1):8. 2003 Dec 19
32. Deen JL, Weber M, Qua S, Fontaine O: An extended field test of the WHO severe malnutrition guidelines in hospitals in developing countries: preliminary observations. Forum Nutr 2003, 56:183-4.
33. Parati G, Mendis S, Aebegunde D, Asmar R, Mieke S, Murray A, Shengelia B, Steenwoorden G, Van Montfrans G, O’Brien E: Recommendations for blood pressure measuring devices for office/clinic use in low resource settings. Blood Press Monit 2005, 10(1):3-10.